Trial Profile
Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 02 Jun 2020 Results from DEFEND-1 (n=53) NCT02284009 finding whether GLP-1 receptor agonist lessen the loss of beta cell function after T1D diagnosis, published in the Journal of Clinical Endocrinology and Metabolism
- 27 Mar 2020 Primary endpoint (Mean change from baseline in stimulated (from Mixed meal tolerance test [MMTT]) plasma C-peptide area under the curve (AUC) at Week 52) has not been met published in the Journal of Clinical Endocrinology and Metabolism
- 27 Mar 2020 Results assessing efficacy and safety of once-weekly albiglutide 30mg (up-titration to 50mg at week 6) versus placebo together with insulin in patients with new-onset type 1 diabetes and residual insulin production published in the Journal of Clinical Endocrinology and Metabolism